Skip to main
CI

Cigna (CI) Stock Forecast & Price Target

Cigna (CI) Analyst Ratings

Based on 18 analyst ratings
Buy
Strong Buy 33%
Buy 56%
Hold 11%
Sell 0%
Strong Sell 0%

Bulls say

Cigna Group is strategically positioned to capitalize on the anticipated $100 billion biosimilars market by 2030, enhancing its growth potential within the pharmacy benefit management arena. The company is expected to generate double-digit savings on GLP-1 net cost developments for its employer clients, further increasing its attractiveness to current and prospective customers. Additionally, the build-out of Evernorth is projected to offset earnings headwinds from economic downturns, as the end markets for this segment demonstrate greater resilience under adverse conditions.

Bears say

The negative outlook on Cigna Group's stock is primarily influenced by several fundamental risks, including potential inaccuracies in pricing and managing healthcare cost trends, which could adversely affect profitability. Additionally, ongoing regulatory scrutiny of pharmacy benefit managers (PBMs) presents a significant uncertainty, potentially delaying client retention and growth initiatives, particularly for the Evernorth segment. Furthermore, macroeconomic factors such as rising unemployment could lead to declines in commercial membership, further straining the company’s financial performance.

Cigna (CI) has been analyzed by 18 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 56% recommend Buy, 11% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Cigna and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Cigna (CI) Forecast

Analysts have given Cigna (CI) a Buy based on their latest research and market trends.

According to 18 analysts, Cigna (CI) has a Buy consensus rating as of Jan 7, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $355.28, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $355.28, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Cigna (CI)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.